<DOC>
	<DOCNO>NCT01796262</DOCNO>
	<brief_summary>The purpose study determine whether docosahexaenoic acid ( DHA ) effective reduce Attention Deficit/Hyperactivity Disorder ( ADHD ) core symptom clinical sample child adolescent ADHD .</brief_summary>
	<brief_title>The Effects DHA Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>The primary objective study investigate relative efficacy tolerability omega-3 fatty acid supplementation , specifically docosahexaenoic acid ( DHA ) , reduce attention-deficit/hyperactivity disorder ( ADHD ) symptoms child . The present study go determine whether DHA supplementation induces modification fatty acid blood level evaluate correlation possible modification behavioral , neuropsychological functional index . The study randomise , placebo-controlled double-blind intervention trial provide within- between-group comparison 6 month . At start study , patient randomize active treatment DHA dose one capsule twice daily , correspond daily dose 500 mg DHA , placebo ( identical capsule fishy odor contain 500 mg wheat germ oil ) . A total 50 patient include study conduct Child Psychiatry Unit `` E. Medea '' Scientific Institute ( northern Italy ) . The study participant recruit among patient assess diagnosed clinic , age 6 14 year , meet DSM-IV criterion diagnosis ADHD subtype ( see Eligibility Criteria detail ) . The study also recruit 20 typically develop child provide control group start research comparison fatty acid blood level outcome measure ( healthy child include supplementation phase ) . Clinical assessment make make three visit site : baseline ( Visit 1 ) , 4 month ( Visit 2 ) 6 month ( Visit 3 ) . At Visits 1-2-3 , blood sample take analysis blood fatty acid profile . At Visit 1 , inform consent sign , inclusion exclusion criterion assess , investigator make medical evaluation , include medical psychiatric history , assessment diagnosis comorbidity parent interview accord DSM-IV criterion ( DAWBA ) . A number examination instrument use , include height weight , pulse blood pressure , neuromotor examination assessment general level function clinical scale questionnaire complete parent ( see Outcome Measure Section detail ) ; several neuropsychological test read test perform developmental neuropsychologist . At Visits 1-2 , change concentration oxygenate Hb deoxygenate Hb prefrontal cortex computerize visual work memory task assess subset patient ( 10 child group ) functional Near-Infrared Spectroscopy . Visit 2 include examination instrument Visit 1 , exception read test ; Visit 3 include measure Visit 1 , exception fNIRS . Parents return every month clinic ass compliance ( define take prescribed dosage 70 % day interval ) , interview current medical symptom adverse event side effect , get supplementation dosage follow month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Clinical diagnosis ADHD base DSMIV criterion confirm Development WellBeing Assessment ( DAWBA ) interview Comorbid disorder accept : mood disorder , anxiety disorder , oppositional defiant disorder , conduct disorder , learn disorder Total IQ equal 85 Aged 6 14 year Autism , Schizophrenia othe psychiatric disorder include inclusion criterion associate neurologic , genetic , infectious metabolic disorder , seizure disorder present past use psychoactive drug</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ADHD</keyword>
	<keyword>DHA</keyword>
	<keyword>neuropsychological task</keyword>
	<keyword>fNIRS</keyword>
	<keyword>Docosahexaenoic Acid</keyword>
	<keyword>n-3 polyunsaturated fatty acid</keyword>
	<keyword>cognition</keyword>
	<keyword>behavior</keyword>
</DOC>